scispace - formally typeset
Search or ask a question
Author

Marie Raffin

Bio: Marie Raffin is an academic researcher from University of Paris. The author has contributed to research in topics: Catatonia & Psychosis. The author has an hindex of 15, co-authored 34 publications receiving 703 citations. Previous affiliations of Marie Raffin include King's College London & Pierre-and-Marie-Curie University.

Papers
More filters
Journal ArticleDOI
TL;DR: It is suggested that clinical status following antipsychotic treatment in schizophrenia is linked to glutamate dysfunction, and treatment with compounds acting on the glutamatergic system might therefore be beneficial in patients who respond poorly to dopaminergic antipsychotics.

161 citations

Journal ArticleDOI
TL;DR: Catatonia in children and adolescents is associated with a high prevalence of medical conditions and this needs to be acknowledged as it may greatly delay the treatment of catatonia and the diagnosis of medically related cat atonia.

67 citations

Journal ArticleDOI
TL;DR: In this article, a combination of functional magnetic resonance imaging and magnetic resonance spectroscopy was used to investigate the relationship between medial temporal activation during an episodic memory task and local glutamate levels in 22 individuals with at-risk mental state for psychosis and 14 healthy volunteers.

57 citations

01 Jan 2011
TL;DR: This study provides the first evidence that links medial temporal dysfunction with the central glutamate system in humans and is consistent with evidence that drugs that modulate glutamatergic transmission might be useful in the treatment of psychosis.
Abstract: Both medial temporal cortical dysfunction and perturbed glutamatergic neurotransmission are regarded as fundamentalpathophysiological features of psychosis. However, although animal models of psychosis suggest that these two abnormalities areinterrelated,theirrelationshipinhumanshasyettobeinvestigated.

55 citations

Journal ArticleDOI
TL;DR: Recent advances in child and adolescent catatonia research have offered major improvements in understandingCatatonia and in new therapeutic opportunities, and advances need to be acknowledged in order to direct patients to centers that have developed a specific expertise.

53 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: This review provides an update on the latest findings on dopamine and glutamate abnormalities in schizophrenia, focusing on in vivo neuroimaging studies in patients and clinical high-risk groups, and considers their implications for understanding the biology and treatment of schizophrenia.
Abstract: The glutamate and dopamine hypotheses are leading theories of the pathoaetiology of schizophrenia. Both were initially based on indirect evidence from pharmacological studies supported by post-mortem findings, but have since been substantially advanced by new lines of evidence from in vivo imaging studies. This review provides an update on the latest findings on dopamine and glutamate abnormalities in schizophrenia, focusing on in vivo neuroimaging studies in patients and clinical high-risk groups, and considers their implications for understanding the biology and treatment of schizophrenia. These findings have refined both the dopamine and glutamate hypotheses, enabling greater anatomical and functional specificity, and have been complemented by preclinical evidence showing how the risk factors for schizophrenia impact on the dopamine and glutamate systems. The implications of this new evidence for understanding the development and treatment of schizophrenia are considered, and the gaps in current knowledge highlighted. Finally, the evidence for an integrated model of the interactions between the glutamate and dopamine systems is reviewed, and future directions discussed.

590 citations

Journal ArticleDOI
TL;DR: The underlying concepts of DL are introduced and studies that have used this approach to classify brain‐based disorders are reviewed, indicating that DL could be a powerful tool in the current search for biomarkers of psychiatric and neurologic disease.

455 citations

Journal ArticleDOI
TL;DR: Findings suggest that CBD has beneficial effects in patients with schizophrenia, and this agent may represent a new class of treatment for the disorder.
Abstract: Objective:Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.Method:In an exploratory double-blind parallel-group trial, patients with schizophrenia were randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication. Participants were assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).Results:After 6 weeks of treatment, compared with the placebo group, the CBD group had lower levels of positive psychotic symptoms (PANSS: treatment difference=−1.4, 95% CI=−2.5, −0.2) and were more likely to have been rated as improved (CGI-I: treatment difference=−0.5, 95% CI=−0....

408 citations

Journal ArticleDOI
TL;DR: This work quantitatively characterize the univariate wavelet entropy of regional activity, the bivariate pairwise functional connectivity between regions, and the multivariate network organization of connectivity patterns, and develops a general statistical framework for the testing of group differences in network properties, broadly applicable to studies where changes in network organization are crucial to the understanding of brain function.

398 citations